Predictive biomarkers of everolimus efficacy in HER2+advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.

被引：7

作者：

Slamon, Dennis J.

Hurvitz, Sara A.

Chen, David

Andre, Fabrice

Tseng, Ling-Ming

Jerusalem, Guy Heinrich Maria

Wilks, Sharon

O'Regan, Ruth

Isaacs, Claudine

Toi, Masakazu

Burris, Howard A.

He, Wei

Riester, Markus

Robinson, Douglas

Taran, Tanya

Gianni, Luca

机构：

[1] Univ Calif Los Angeles, Sch Med, Translat Oncol Res Lab, Los Angeles, CA USA

[2] Univ Calif Los Angeles, Healthcare Hematol Oncol Breast Oncol Program, Santa Monica, CA USA

[3] Novartis Pharmaceut, E Hanover, NJ USA

[4] Inst Gustave Roussy, Villejuif, France

[5] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan

[6] Ctr Hosp Univ, Liege, Belgium

[7] US Oncol Canc Care Ctr South Texas, San Antonio, TX USA

[8] Emory Univ, Atlanta, GA 30322 USA

[9] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[10] Kyoto Univ, Grad Sch Med, Kyoto, Japan

[11] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[12] Novartis Pharmaceut, E Hanover, NJ USA

[13] Novartis Inst BioMed Res Inc, Cambridge, MA USA

[14] Hosp San Raffaele, I-20132 Milan, Italy

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.512

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

512

引用

页数：1